Connect with us

Health and Wellness

Are you considering taking a weight loss drug like Ozempic? Here are some potential risks and benefits

Published

on


When weight loss drugs like Ozempic appeared available on the market, celebrities and social media influencers quickly began reaping their benefits, resulting in a rapid increase of their use. In the last three months of 2022, doctors within the United States alone wrote over nine million prescriptions for these drugs.

As their popularity has increased, we have also heard more about their potential unwanted effects, from common gastrointestinal complaints to more serious mental health issues.

But what does the science say about how well Ozempic and Wegovy (each brand names of the drug semaglutide) work for weight loss? What are the potential unwanted effects? Here’s what to contemplate if you or a loved one is fascinated with taking the drug.



Possible profits

1) It will probably help you lose weight

The largest, well run Research work semaglutide originated within the UK in 2021. About 1,961 people classified as “overweight” or “obese” were randomly assigned to receive semaglutide or placebo and were followed for 68 weeks (about 1.3 years). All participants also had free access to advice on healthy eating and physical activity.

The study showed that individuals taking semaglutide lost weight – significantly greater than those taking placebo (-14.9% of body weight compared with -2.4% of body weight).

In one other test within the United States, one medical practice administered weekly injections of semaglutide to 408 people. During the primary three months, the people included in the ultimate evaluation (175 people) lost a mean of 6.7 kg. They lost a mean of 12.3 kg in the primary six months.

Significant weight loss was observed in additional people recent trial semaglutide, suggesting that weight loss is a very likely consequence of continued use of the drug.

On average, people taking semaglutide within the study lost just below 15% of their body weight, compared with 2.4% for those taking placebo.
John Hanson Pye/Shutterstock

2) It can reduce risk aspects for chronic diseases

When chubby or obese people lose weight at the least 5% body weight, physiological changes often transcend changes in body weight or shape. This may include lowered levels of cholesterol, lowered blood pressure and lowered blood glucose levels, which reduces the chance of chronic diseases.

In one in all semaglutide trialsmost individuals (87.3%) lost at the least 5% of their body weight. Although most large studies of semaglutide excluded individuals with metabolic diseases comparable to type 2 diabetes, the metabolic health benefits were noticedincluding decreased blood pressure, blood glucose and fasting blood lipids (fats).

IN UK test as of 2021, people taking semaglutide saw greater improvements in physical performance and risk aspects for heart disease and diabetes, including reductions in waist circumference, reductions in markers of inflammation, blood pressure and blood glucose levels.

3) It can improve your quality of life, emotional well-being, or sense of accomplishment

The original study of semaglutide didn’t deal with this bundle of benefits, but follow-up studies have shown additional benefits related to the drug. Compared to placebo, people taking semaglutide saw significant improvement improvements of their physical functioning and of their perception of their overall health, social functioning and mental health.

Anecdotally (not based on scientific research), people using semaglutide, e.g Oprah Winfreyreport a moment of recovery or a turning point in your life, social situation and body image.

Oprah Winfrey at a recent awards ceremony
Oprah says Ozempic quieted her “food noise.”
Chris Pizzello/AAP

What concerning the risks?

1) Gastrointestinal symptoms may occur

In Clinical trial within the USAalmost half (48.6%) of individuals taking semaglutide reported unwanted effects. The commonest symptoms were nausea and vomiting (36.6%), followed by diarrhea (8.6%), fatigue (6.3%), and constipation (5.7%).

Nausea and diarrhea were also commonly reported within the UK study.

IN next try, many participants (74.2%) using semaglutide reported gastrointestinal symptoms. However, almost half (47.9%) of placebo users also reported gastrointestinal symptoms, indicating that symptoms could also be just like those experienced during normal, on a regular basis life.

Most gastrointestinal symptoms were mild to moderate in severity and resolved without discontinuation in most subjects.

2) You may feel drained

Fatigue was the second commonest side effect amongst US participants clinical examinationaffecting 6.3% of participants.

A person holds an Ozempic injection
The commonest symptoms are gastrointestinal symptoms, followed by fatigue.
fcm82/Shutterstock

3) You could also be within the minority who cannot tolerate the drug

The Australian Therapeutic Goods Agency (TGA) yes approved Ozempic as protected for treating type 2 diabetes, but not yet approved to be used for weight loss. TGA has it too approved Wegovy (higher dose semagtlutide) for weight loss, nevertheless it is just not yet available in Australia.

In United States clinical examinationNo unexpected issues of safety were reported. However, five patients (2.9%) needed to stop taking the drug because they might not tolerate the unwanted effects. Fifteen (8.6%) needed to either reduce their dose or stay on the identical dose to avoid unwanted effects.

IN other researchsome patients discontinued the study because their gastrointestinal symptoms were so severe that they might not tolerate further treatment.

More serious safety concerns have been reported in studies include gallbladder-related disease (mainly cholelithiasis, also often called gallstones) in 34 patients (2.6%) and mild acute pancreatitis in three patients (0.2%). All subjects recovered through the trial period.

European 2024 test analyzed psychiatric opposed events related to the usage of semaglutide, liraglutide, and tirzepatide (which act in a similar strategy to semaglutide). In the period from January 2021 to May 2023, 481 psychiatric events (roughly 1.2% of all reported) related to those drugs were registered within the drug database. About half of those events were reported as depression, followed by anxiety (39%) and suicidal ideation (19.6%). Nine deaths and 11 life-threatening cases were reported through the study period.

Due to the seriousness and dire consequences of some of those reports, US Food and Drug Administration further studies were carried out, but no evidence was found that the usage of these drugs causes suicidal thoughts or actions.

4) Access could also be difficult

Despite being considered protected, the TGA is warned significant barriers to access to Ozempic feedstock are more likely to remain throughout 2024.

To address shortages, pharmacists should give preference to individuals with type 2 diabetes searching for the drug.

5) You cannot at all times get clear information from special interests

Given the recognition of Ozempic and Wegova, health organizations comparable to the World Obesity Federation have expressed this apprehension about drug marketing, PR and power presence on social media.

Some journalists are like that raised concerns about conflict of interest on the connection between some obesity researchers and the manufacturers of Novo Nordrisk, Ozempic and Wegovy. There is concern that the connection with Novo Nordrisk could influence researchers to provide trial results that are more favorable to the drugs.

Conclusion

Ozempic is a medicine that ought to be used together with your doctor. Remember, nevertheless, that weight is simply one aspect of your health and well-being. It’s vital to have a look at your health holistically and prioritize eating well, exercising more, and getting enough sleep.


This article was originally published on : theconversation.com
Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health and Wellness

Jury awarded $310 million to parents of teenager who died after falling on a ride at Florida amusement park – Essence

Published

on

By

Sun Sentinel/Getty Images

The family of Tire Sampson, the 14-yr-old who tragically died on an amusement park ride in Orlando, Florida, in 2022, has been awarded $310 million in a civil lawsuit.

Tire, who was visiting ICON Park along with his family on March 24, 2022, fell from the FreeFall drop tower. Although he was taken to a nearby hospital, he didn’t survive his injuries.

Now, greater than two years later, a jury has held the vehicle manufacturer, Austria-based Funtime Handels, responsible for the accident and awarded the Tire family $310 million. According to reports from local news stations WFTV AND KSDKthe jury reached its verdict after about an hour of deliberation.

Tyre’s parents will each receive $155 million, according to attorney spokesman Michael Haggard.

Attorneys Ben Crump and Natalie Jackson, who represented Tyre’s family, shared their thoughts on this landmark decision via X (formerly Twitter). “This ruling is a step forward in holding corporations accountable for the safety of their products,” they said in a statement.

Lawyers stressed that Tyre’s death was attributable to “gross negligence and a failure to put safety before profits.” They added that the ride’s manufacturer had “neglected its duty to protect passengers” and that the substantial award ensured it could “face the consequences of its decisions.”

Crump and Jackson said they hope the result will encourage change throughout the theme park industry. “We hope this will spur the entire industry to enforce more stringent safety measures,” they said. “Tire heritage will provide a safer future for drivers around the world.”

An investigation previously found that Tyre’s harness was locked through the descent, but he dislodged from his seat through the 430-foot fall when the magnets engaged. Tire’s death was ruled the result of “multiple injuries and trauma.”

ICON Park said at the time that it could “fully cooperate” with the authorities.

This article was originally published on : www.essence.com
Continue Reading

Health and Wellness

Tireless HIV/AIDS advocate A. Cornelius Baker dies

Published

on

By

HIV/AIDS Advocate, A. Cornelius Baker


A. Cornelius Baker, a tireless advocate of HIV and AIDS testing, research and vaccination, died Nov. 8 at his home in Washington, D.C., of hypertensive, atherosclerotic heart problems, in response to his partner, Gregory Nevins.

As previously reported, Baker was an early supporter for people living with HIV and AIDS within the Nineteen Eighties, when misinformation and fear-mongering in regards to the disease were rampant.

According to Douglas M. Brooks, director of the Office of National AIDS Policy under President Obama, it was Baker’s Christian faith that guided him toward compassion for others.

“He was very kind, very warm and inclusive – his circles, both professional and personal, were the most diverse I have ever seen, and he was guided by his Christian values,” Brooks told the outlet. “His ferocity was on display when people were marginalized, rejected or forgotten.”

In 1995, when he was executive director of the National AIDS Association, Baker pushed for June 27 to be designated National HIV Testing Day.

In 2012, he later wrote on the web site of the Global Health Advisor for which he was a technical advisor that: “These efforts were intended to help reduce the stigma associated with HIV testing and normalize it as part of regular screening.”

https://twitter.com/NBJContheMove/status/1856725113967632663?s=19

Baker also feared that men like himself, black gay men, and other men from marginalized communities were disproportionately affected by HIV and AIDS.

Baker pressured the Clinton administration to incorporate black and Latino people in clinical drug trials, and in 1994 he pointedly told the Clinton administration that he was bored with hearing guarantees but seeing no motion.

According to Lambda Legal CEO Kevin Jennings, yes that daring attitude that defines Baker’s legacy in the world of ​​HIV/AIDS promotion.

“Cornelius was a legendary leader in the fight for equality for LGBTQ+ people and all people living with HIV,” Jennings said in a press release. “In the more than twenty years that I knew him, I was continually impressed not only by how effective he was as a leader, but also by how he managed to strike the balance between being fierce and kind at the same time. His loss is devastating.”

Jennings continued: “Cornelius’ leadership can’t be overstated. For many years, he was one in all the nation’s leading HIV/AIDS warriors, working locally, nationally and internationally. No matter where he went, he proudly supported the HIV/AIDS community from the Nineteen Eighties until his death, serving in various positions including the Department of Health and Human Services, the National Association of Persons with Disabilities AIDS, and the Whitman-Walker Clinic . Jennings explained.

Jennings concluded: “His career also included several honors, including being the first recipient of the American Foundation for AIDS Research Foundation’s organization-building Courage Award. Our communities have lost a pillar in Cornelius, and as we mourn his death, we will be forever grateful for his decades of service to the community.”

Kaye Hayes, deputy assistant secretary for communicable diseases and director of the Office of Infectious Diseases and HIV/AIDS Policy, in her comment about his legacy, she called Baker “the North Star.”.

“It is difficult to overstate the impact his loss had on public health, the HIV/AIDS community or the place he held in my heart personally,” Hayes told Hiv.gov. “He was pushing us, charging us, pulling us, pushing us. With his unwavering commitment to the HIV movement, he represented the north star, constructing coalitions across sectors and dealing with leaders across the political spectrum to deal with health disparities and advocate for access to HIV treatment and look after all. He said, “The work isn’t done, the charge is still there, move on – you know what you have to do.” It’s in my ear and in my heart in the case of this job.

Hayes added: “His death is a significant loss to the public health community and to the many others who benefited from Cornelius’ vigilance. His legacy will continue to inspire and motivate us all.”

Baker is survived by his mother, Shirley Baker; his partner Nevins, who can be senior counsel at Lambda Legal; his sisters Chandrika Baker, Nadine Wallace and Yavodka Bishop; in addition to his two brothers, Kareem and Roosevelt Dowdell; along with the larger HIV/AIDS advocacy community.


This article was originally published on : www.blackenterprise.com
Continue Reading

Health and Wellness

Bovaer is added to cow feed to reduce methane emissions. Does it pass into milk and meat? And is it harmful to humans?

Published

on

By

There are growing concerns in regards to the use of feed supplements, Bowar 10to reduce methane production in cows.

Bovaer 10 consists of silicon dioxide (mainly sand), propylene glycol (food stabilizer approved by Food Safety Australia New Zealand) and lively substance 3-nitrooxypropanol (3-NOP).

There has been an enormous amount of misinformation in regards to the safety of 3-NOP, with some milk from herds fed this additive being labeled “Frankenmilk”. Others feared it could get to humans through beef.

The most significant thing is that 3-NOP is secure. Let’s clear up some major misconceptions.

Why do we want to limit methane production?

In our attempts to limit global warming, we’ve placed the best emphasis on CO₂ because the major man-made greenhouse gas. But methane is also a greenhouse gas, and although we produce less of it, it is: a much stronger greenhouse gas than CO₂.

Agriculture is the largest a man-made source of methane. As cattle herds expand to meet our growing demand for meat and milk, reducing methane production from cows is a vital way to reduce greenhouse gas emissions.

There are several ways to do that. Stopping bacteria within the stomachs of cows that produce methane one approach is to produce methane.

The methane produced by cows and sheep doesn’t come from the animals themselves, but from the microbes living of their digestive systems. 3-NO stop the enzymes that perform the last step of methane synthesis in these microorganisms.

3-NOP is not the one compound tested as a feed additive. Australian product based on seaweed, Rumin8for instance, it is also in development. Saponins, soap-like chemicals present in plants, and essential oils as well has been examined.

However, 3-NOP is currently one of the popular effective treatments.

Nitrooxypropanol structure: red balls are oxygen, gray carbon, blue nitrogen and white hydrogen.
PubChem

But is not it poison?

There are concerns on social media that Bovaer is “poisoning our food.”

But, as we are saying in toxicology, it’s the dose that makes the poison. For example, arsenic is deadly 2–20 milligrams per kilogram of body weight.

In contrast, 3-NOP was not lethal on the doses utilized in safety studies, up to 600 mg 3-NOP per kg body weight. At a dose of 100 mg per kg body weight in rats, it didn’t cause any adversarial effects.

What about reproductive issues?

The effect of 3-NOP on the reproductive organs has generated numerous commentary.

Studies in rats and cows showed that doses of 300–500 mg per kg body weight caused: contraction of the ovaries and testicles.

In comparison, to achieve the identical exposure in humans, a 70 kg human would want to eat 21–35 grams (about 2 tablespoons) of pure 3-NOP every day for a lot of weeks to see this effect.

No human will likely be exposed to this amount because 3-NOP doesn’t pass into milk – is fully metabolized within the cow’s intestines.

No cow will likely be exposed to these levels either.

The cow licks itself
Cows will not be exposed to levels tested on animals in laboratory studies.
Ground photo/Shutterstock

What about cancer?

3-NOP is not genotoxic or mutagenicwhich implies it cannot damage DNA. Thus, the results of 3-NOP are dose-limited, meaning that small doses will not be harmful, while very high doses are (unlike radiation where there is no secure dose).

Scientists found that at a dose of 300 mg per kilogram of body weight benign tumors of the small intestine of female ratsbut not male rats, after 2 years of every day consumption. At a dose of 100 mg 3-NOP per kg body weight, no tumors were observed.

Cows eat lower than 2 grams of Bovaer 10 per day (of which only 10% or 0.2 grams is 3-NOP). This is about 1,000 times lower than the appropriate every day intake 1 mg 3-NOP per kg body weight per day for a cow weighing 450 kg.

This level of consumption will likely be not the result in cancer or any of them other adversarial effects.

So how much are people exposed to?

Milk and meat consumers will likely be exposed to zero 3-NOP. 3-NOP doesn’t penetrate milk and meat: is completely metabolized within the cow’s intestines.

Farmers could also be exposed to small amounts of the feed additive, and industrial employees producing 3-NOP will potentially be exposed to larger amounts. Farmers and industrial employees already wear personal protective equipment to reduce exposure to other agricultural chemicals – and it is advisable to do that with Bovear 10 as well.

Milk
3-NOP doesn’t penetrate milk and meat.
Shutterstock

How widely has it been tested?

3-NOP has been in development for 15 years and has been subject to multiple reviews by European Food Safety Authority, UK Food Safety Authority AND others.

It has been extensively tested over months of exposure to cattle and has produced no unintended effects. Some studies actually say so improves the standard of milk and meat.

Bovaer was approved for use in dairy cattle by the European Union from 2022 and Japan in 2024. It is also utilized in many other countries, including: in beef products, amongst others Australia.

A really small amount of 3-NOP enters the environment (lower than 0.2% of the dose taken), no accumulates and is easily decomposed subsequently, it doesn’t pose a threat to the environment.

Since humans will not be exposed to 3-NOP through milk and meat, long-term exposure is not an issue.

What does Bill Gates have to do with this?

Bill Gates has invested in a distinct feed processing method for methane, Australian seaweed-based Rumin8. But he has nothing to do with Bovaer 10.

The Bill & Melinda Gates Foundation awarded research grants to the corporate producing 3-NOP for malaria control researchnot for 3-NOP.

The bottom line is that adding 3-NOP to animal feed doesn’t pose any risk to consumers, animals or the environment.

This article was originally published on : theconversation.com
Continue Reading
Advertisement

OUR NEWSLETTER

Subscribe Us To Receive Our Latest News Directly In Your Inbox!

We don’t spam! Read our privacy policy for more info.

Trending